Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Additionally we are shipping CD79b Molecule, Immunoglobulin-Associated beta Proteins (18) and CD79b Molecule, Immunoglobulin-Associated beta Kits (3) and many more products for this protein.
Showing 10 out of 362 products:
Dog (Canine) Monoclonal CD79B Primary Antibody for FACS - ABIN119698
NOYES, DOMM, WILLSLC: Regulation of erythropoiesis. I. Erythropoietin assay as a clinical tool. in Blood 1970
Show all 3 references for ABIN119698
Dog (Canine) Monoclonal CD79B Primary Antibody for FACS - ABIN320081
Dornan, Bennett, Chen, Dennis, Eaton, Elkins, French, Go, Jack, Junutula, Koeppen, Lau, McBride, Rawstron, Shi, Yu, Yu, Yue, Zheng, Ebens, Polson: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. in Blood 2009
Show all 3 references for ABIN320081
Human Monoclonal CD79B Primary Antibody for FACS - ABIN119706
Jansky, Vybiral: Thermal homeostasis in systemic inflammation: modulation of neuronal mechanisms. in Frontiers in bioscience : a journal and virtual library 2004
Show all 2 references for ABIN119706
Mouse (Murine) Monoclonal CD79B Primary Antibody for FACS, IHC (fro) - ABIN371130
Koyama, Ishihara, Karasuyama, Cordell, Iwamoto, Nakamura: CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. in International immunology 1998
B-cell inhibition by cross-linking CD79b (show PDPK1 Antibodies) is superior to B (show TDO2 Antibodies)-cell depletion with anti-CD20 (show MS4A1 Antibodies) antibodies in treating murine collagen-induced arthritis.
Data indicate that in the absence of DGKzeta (show DGKZ Antibodies), the threshold for B cell antigen receptor (BCR (show BCR Antibodies)) signaling, measured as activation of the Ras-extracellular signal-regulated kinase (ERK (show EPHB2 Antibodies)) pathway, was markedly reduced in mature follicular B cells.
The cytoplasmic tail of IgG1 is strictly required for the surface expression of IgG1 when the expression of Iga/Igb heterodimer is down-regulated in B lymphoma.
endocytosed BCR (show BCR Antibodies) sequentially regulates MAPK (show MAPK1 Antibodies) and Akt (show AKT1 Antibodies) signaling pathways from intracellular compartments
Spontaneous mutation in the Cd79b (show PDPK1 Antibodies) gene leads to a block in B-lymphocyte (show AKAP17A Antibodies) development at the C' (early pre-B) stage
The VHDJH recombination process at the IgH locus and the survival of pro-B cells that carry these rearrangements do not depend on the expression of Ig-beta molecules.
Deletion in developing B cells leads to cell death; Igbeta expression is essential to maintain preB (show PREB Antibodies) cell and immature B cell survival and to mediate B cell differentiation
MHC II structural requirements for mediation of cell death signaling in a murine B cell lymphoma with Igalpha/beta
hotspot mutations of CD79B Y196 and MYD88 (show MYD88 Antibodies) L265 may serve as a genetic hallmark for primary central nervous system lymphoma
CD79B overexpression leading to activation of AKT (show AKT1 Antibodies)/MAPK (show MAPK1 Antibodies) is a potential mechanism underlying primary ibrutinib resistance in ABC (show ABCB6 Antibodies)-DLBCL, and support its utility as an effective biomarker to predict therapeutic response to ibrutinib.
Novel CD79B variations in mature B-cell non-Hodgkin's lymphoma patients were detected.
MYD88 (show MYD88 Antibodies) L265P and CD79B mutations were frequently detected in primary breast diffuse large B-cell lymphoma.
Oncogenic CD79B mutation is associated with primary diffuse large B-cell lymphomas of central nervous system.
Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 (show MYD88 Antibodies) and CD79B mutations.
Abberant expression of CD79b in non-B cells caused unwanted reactivity, rendering CD79b unsuitable for T-cell receptor - based immunotherapies.
Phosphorylation of CD79a (show CD79A Antibodies) causes a decrease in helical propensity in the C-terminal region, for CD79b, the opposite was observed and phosphorylation resulted in an increase of helical propensity in the C-terminal part.
results suggest that MYD88 (show MYD88 Antibodies) mutations, and to a lesser extent CD79B mutations, are important drivers of lymphomagenesis in PTL (show PNLIP Antibodies)
CD79B and MYD88 (show MYD88 Antibodies) mutations are associated with an older age at onset in diffuse large b-cell lymphoma with a significant overlap, which did not affect the outcome of the disease.
The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described.
B-cell antigen receptor complex-associated protein beta chain
, B-cell-specific glycoprotein B29
, immunoglobulin-associated B29 protein
, immunoglobulin-associated beta
, CD79b antigen (immunoglobulin-associated beta)
, CD79B antigen